Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CSTL 
Castle Biosciences Inc (CSTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: CSTL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $35.62
1 Year Target Price $35.62
| 8 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -75.4% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 574.94M USD | Price to earnings Ratio - | 1Y Target Price 35.62 |
Price to earnings Ratio - | 1Y Target Price 35.62 | ||
Volume (30-day avg) 9 | Beta 1.09 | 52 Weeks Range 14.59 - 35.84 | Updated Date 08/15/2025 |
52 Weeks Range 14.59 - 35.84 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When - | Estimate -0.51 | Actual 0.15 |
Profitability
Profit Margin -2.73% | Operating Margin (TTM) -4.93% |
Management Effectiveness
Return on Assets (TTM) -2.79% | Return on Equity (TTM) -2.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 336366129 | Price to Sales(TTM) 1.66 |
Enterprise Value 336366129 | Price to Sales(TTM) 1.66 | ||
Enterprise Value to Revenue 0.97 | Enterprise Value to EBITDA 10.33 | Shares Outstanding 29008300 | Shares Floating 26622930 |
Shares Outstanding 29008300 | Shares Floating 26622930 | ||
Percent Insiders 3.16 | Percent Institutions 94.26 |
Upturn AI SWOT
Castle Biosciences Inc
Company Overview
History and Background
Castle Biosciences Inc. was founded in 2005 and is a dermatologic cancer company focused on providing personalized genomic information to improve cancer treatment decisions. They have grown through internal development and strategic acquisitions, expanding their test offerings to address various skin cancer types.
Core Business Areas
- Dermatology: Offers tests like DecisionDx-Melanoma, DecisionDx-SCC, and DecisionDx-DiffDx-Melanoma to provide prognostic and diagnostic information for skin cancers.
- Other: Includes tests for uveal melanoma (DecisionDx-UM) and Barrett's Esophagus (TissueCypher Barrett's Esophagus Assay).
Leadership and Structure
The leadership team is headed by Derek Maetzold (President & CEO). The organizational structure includes departments focused on research and development, commercial operations, medical affairs, and finance.
Top Products and Market Share
Key Offerings
- DecisionDx-Melanoma: A gene expression profile (GEP) test that predicts the risk of metastasis in cutaneous melanoma. Competitors include Myriad Genetics (although they have exited the dermatology market) and other emerging genomic testing companies. Market share is estimated to be significant within the cutaneous melanoma prognostic testing market; estimated at 60%.
- DecisionDx-SCC: A GEP test that predicts the risk of metastasis in cutaneous squamous cell carcinoma (SCC). Competitors include other molecular diagnostic companies exploring similar tests, but currently, DecisionDx-SCC is a leading assay. Market share is difficult to assess precisely due to the evolving competitive landscape but is considered substantial for high-risk SCC.
- DecisionDx-UM: A GEP test for uveal melanoma that predicts risk of metastasis. It's considered a standard of care. Competitors are limited due to the specialized nature of uveal melanoma testing. Market share is estimated to be above 80% within the US market for this testing modality.
Market Dynamics
Industry Overview
The industry comprises molecular diagnostics companies specializing in genomic testing for cancer. Personalized medicine and precision oncology are driving growth. Increasing awareness of genomic testing benefits and advancements in technology fuel market expansion.
Positioning
Castle Biosciences is a leading provider of prognostic and diagnostic genomic tests for dermatologic cancers and other oncology areas. Their competitive advantages include established tests, strong clinical evidence, and a specialized focus on dermatologic oncology.
Total Addressable Market (TAM)
The TAM for Castle Biosciences is estimated to be in the billions of dollars, considering the prevalence of skin cancers and the expansion into new indications. Castle Biosciences is well-positioned to capture a significant portion of this TAM through its existing tests and future product development.
Upturn SWOT Analysis
Strengths
- Proprietary gene expression profiling technology
- Strong clinical validation data
- Established reimbursement pathways
- Focus on underserved markets in dermatologic oncology
- Experienced management team
Weaknesses
- Reliance on a limited number of tests
- Susceptibility to changes in reimbursement policies
- Dependence on physician adoption of genomic testing
- Negative gross margins for DecisionDx DiffDx-Melanoma
- Need to continue to innovate and acquire new technologies
Opportunities
- Expanding test offerings into new cancer types
- Increasing market penetration through education and awareness
- Forging partnerships with pharmaceutical companies
- Developing new diagnostic and prognostic tools
- International expansion
Threats
- Competition from other molecular diagnostic companies
- Changes in reimbursement policies
- Technological advancements rendering existing tests obsolete
- Economic downturn impacting healthcare spending
- Regulatory hurdles for new tests
Competitors and Market Share
Key Competitors
- MIRM
- NSTG
Competitive Landscape
Castle Biosciences holds a strong position in the dermatologic cancer genomic testing market. MIRM and NSTG are significant players in similar areas like cancer diagnostics, offering some overlapping and competing products. The space is complex and changing and marketshare can change based on acquisitions
Major Acquisitions
AltheaDx
- Year: 2021
- Acquisition Price (USD millions): 145
- Strategic Rationale: Expanded Castle Biosciences' portfolio into gastroenterology with the TissueCypher Barrett's Esophagus Assay.
MyPath Labs
- Year: 2022
- Acquisition Price (USD millions): 32.5
- Strategic Rationale: Added complementary tests and expertise in dermatopathology.
Growth Trajectory and Initiatives
Historical Growth: Castle Biosciences has demonstrated strong revenue growth driven by increasing adoption of its genomic tests.
Future Projections: Analyst estimates vary, but project continued revenue growth driven by market expansion and new test development.
Recent Initiatives: Recent initiatives include acquisitions of companies like AltheaDx and MyPath Labs, expanding the test menu and market reach. Expansion of the sales force and increased marketing efforts are also key initiatives.
Summary
Castle Biosciences is a specialized genomic testing company with a focus on dermatology, showing promising growth in revenue, partially offset by significant losses. Its strong suit is its focus on underserved markets in dermatologic oncology where they have established tests with strong data and reimbursement. Competitors and future potential for reimbursement policy changes are important to monitor, along with technological advancements that can make their existing tests obsolete.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Investor Presentations
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and may vary. Financial data is not real-time and may be outdated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Castle Biosciences Inc
Exchange NASDAQ | Headquaters Friendswood, TX, United States | ||
IPO Launch date 2019-07-25 | Founder, CEO, President & Director Mr. Derek J. Maetzold | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 798 | Website https://castlebiosciences.com |
Full time employees 798 | Website https://castlebiosciences.com | ||
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.